Status: Recruiting
EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors
This trial investigates a new drug, EIS-12656, in participants with specified advanced solid tumors carrying pre-specified mutations. The trial consists of a dose escalation part (Phase 1) and a dose expansion part (Phase 2).
Participants needed: 144
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Eisbach Bio GmbHUpdated: Sep 19, 2024Locations: 1
Eligibility criteria
Recurrent locally advanced or metastatic solid tumors [+6]
History or evidence of any clinically relevant gastrointestinal disease [+3]